BEAM

24.50

0.45% 0.11

Dopo l'orario di chiusura: 24.41 -0.09 -0.37%

Beam Therapeutics Inc (BEAM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BEAM Giù? Forum Previsione

Precedente Chiudi:

$24.39

Aprire:

$25

Volume 24 ore:

1.50M

Relative Volume:

0.76

Capitalizzazione di mercato:

$2.53B

Reddito:

$164.01M

Utile/perdita netta:

$-65.04M

Rapporto P/E:

-35.66

EPS:

-0.687

Flusso di cassa netto:

$-383.84M

1 W Prestazione:

+0.95%

1M Prestazione:

-16.35%

6M Prestazione:

-0.65%

1 anno Prestazione:

-4.26%

Intervallo 1D:

$24.21

$25.48

Intervallo di 1 settimana:

$23.44

$25.48

Portata 52W:

$20.23

$38.26

Beam Therapeutics Inc Stock (BEAM) Company Profile

Nome

Beam Therapeutics Inc

Settore

Healthcare (1064)

Industria

Biotechnology (595)

Telefono

857-327-8775

Indirizzo

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Dipendente

522

Cinguettio

Prossima data di guadagno

2026-11-03

Ultimi documenti SEC

BEAM's Discussions on Twitter

Compare BEAM vs VRTX, MRNA, REGN, ARGX, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BEAM Beam Therapeutics Inc	24.50	2.51B	164.01M	-65.04M	-383.84M	-0.687
VRTX Vertex Pharmaceuticals Inc	504.73	133.37B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-20	Iniziato	Canaccord Genuity	Buy
2025-10-09	Iniziato	Jefferies	Buy
2025-03-28	Aggiornamento	BofA Securities	Neutral → Buy
2025-03-10	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-01-29	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-11-06	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-07-23	Iniziato	H.C. Wainwright	Buy
2024-01-29	Aggiornamento	JP Morgan	Neutral → Overweight
2023-12-15	Downgrade	BofA Securities	Buy → Neutral
2023-12-08	Downgrade	Jefferies	Buy → Hold
2023-10-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-20	Downgrade	Leerink Partners	Outperform → Market Perform
2023-03-21	Iniziato	Bernstein	Mkt Perform
2023-02-01	Iniziato	Cantor Fitzgerald	Overweight
2022-12-20	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2022-12-13	Iniziato	Citigroup	Buy
2022-06-17	Iniziato	BMO Capital Markets	Market Perform
2022-04-28	Iniziato	Credit Suisse	Neutral
2022-01-05	Iniziato	Guggenheim	Buy
2021-10-19	Iniziato	SVB Leerink	Outperform
2021-09-24	Ripresa	Stifel	Buy
2021-09-10	Iniziato	BofA Securities	Buy
2021-05-11	Iniziato	Redburn	Buy
2021-05-04	Iniziato	RBC Capital Mkts	Sector Perform
2021-03-01	Downgrade	Barclays	Overweight → Equal Weight
2021-02-16	Iniziato	Wells Fargo	Overweight
2021-01-29	Downgrade	JP Morgan	Overweight → Neutral
2021-01-06	Iniziato	Stifel	Hold
2020-08-05	Iniziato	William Blair	Outperform
2020-03-02	Iniziato	Barclays	Overweight
2020-03-02	Iniziato	JP Morgan	Overweight
2020-03-02	Iniziato	Jefferies	Buy
2020-03-02	Iniziato	Wedbush	Outperform

Mostra tutto

Beam Therapeutics Inc Borsa (BEAM) Ultime notizie

Oct 01, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire

Oct 01, 2026

Sep 30, 2026

Will IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) Narrative - Yahoo Finance

Sep 30, 2026

Beam says Chinese firm, Serapha stole trade secrets (BEAM) - Seeking Alpha

Sep 30, 2026

Three biotech updates, including accusations of theft and and a new lobbying leader - statnews.com

Sep 30, 2026

(BEAM) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Sep 30, 2026

Sep 29, 2026

Beam sues 2 biotechs, alleging theft of base editing trade secrets - BioPharma Dive

Sep 29, 2026

Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca

Sep 29, 2026

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM) - Seeking Alpha

Sep 29, 2026

Sep 28, 2026

As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock - Barchart.com

Sep 28, 2026

Beam Says Scientist Stole Secrets for Her Chinese Rival Startup - Bloomberg Law News

Sep 28, 2026

Sep 27, 2026

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits

Sep 27, 2026

Sep 26, 2026